Early results from 63 of the infants enrolled in the trial found the vaccine to be safe, tolerated and able to cut the chance ...

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

Along with holiday arrangements, changing seasons signal the need for another type of preparation: vaccination.

“Stress and strain that the acute illness can put on your body can activate or worsen some other underlying disease processes. Probably the most significant is heart disease, heart failure or major ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

Vaccination rates for respiratory viruses that ramp up each winter are lower than medical professionals would hope, but there ...